Free Trial
NASDAQ:PCVX

Vaxcyte Q1 2024 Earnings Report

Vaxcyte logo
$32.60 -0.20 (-0.61%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$32.51 -0.09 (-0.28%)
As of 05/30/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte EPS Results

Actual EPS
-$0.85
Consensus EPS
-$1.13
Beat/Miss
Beat by +$0.28
One Year Ago EPS
N/A

Vaxcyte Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxcyte Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Vaxcyte's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vaxcyte Earnings Headlines

“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
Vaxcyte appoints new independent director
See More Vaxcyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email.

About Vaxcyte

Vaxcyte (NASDAQ:PCVX), a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

View Vaxcyte Profile

More Earnings Resources from MarketBeat